Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma

BACKGROUND: immunotherapy became the first line treatment of metastatic renal cell carcinoma (mRCC). Nevertheless, a better understanding of the specificities of targeted therapies (TT) in the elderly population could be helpful in order to improve the management of mRCC in this population. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupuis, Hugo Georges Arthur, Chebbi, Ala, Surlemont, Louis, Rigal, Olivier, Di Fiore, Frédéric, Pfister, Christian, Nouhaud, François-Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261413/
https://www.ncbi.nlm.nih.gov/pubmed/34295728
http://dx.doi.org/10.21037/tau-20-1481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261413/
https://www.ncbi.nlm.nih.gov/pubmed/34295728
http://dx.doi.org/10.21037/tau-20-1481

Ejemplares similares